Authors' reply

Line Winther Gustafson^{1

2}, Mette Tranberg¹, Pia Nørgaard Christensen³, Rikke Brøndum³, Nicolas Wentzensen⁴, Megan A Clarke⁴, Berit Andersen^{1

5}, Lone Kjeld Petersen^{6

7}, Pinar Bor^{5

8}, Anne Hammer^{5

9}

Affiliations

¹ Department of Public Health Programmes, University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark.
² Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus, Denmark.
³ Department of Pathology, Randers Regional Hospital, Randers, Denmark.
⁴ Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
⁵ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁶ Department of Obstetrics and Gynaecology, Odense University Hospital and Department, Odense, Denmark.
⁷ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁸ Department of Obstetrics and Gynaecology, Randers Regional Hospital, Randers, Denmark.
⁹ Department of Obstetrics and Gynaecology, NIDO, Gødstrup Hospital, Herning, Denmark.

Line Winther Gustafson et al. BJOG. 2024 Jan.

. 2024 Jan;131(1):116-117.

doi: 10.1111/1471-0528.17657. Epub 2023 Sep 5.

¹ Department of Public Health Programmes, University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark.
² Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus, Denmark.
³ Department of Pathology, Randers Regional Hospital, Randers, Denmark.
⁴ Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
⁵ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁶ Department of Obstetrics and Gynaecology, Odense University Hospital and Department, Odense, Denmark.
⁷ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁸ Department of Obstetrics and Gynaecology, Randers Regional Hospital, Randers, Denmark.
⁹ Department of Obstetrics and Gynaecology, NIDO, Gødstrup Hospital, Herning, Denmark.

No abstract available

References

1. Rauf SA, Zehra SA, Shah HH, Beyond P16/Ki67 dual-stain cytology: Exploring alternative biomarkers for diagnosing cervical cancer and its precursors. BJOG. 2023. https://doi.org/10.1111/1471-0528.17577
1. Gustafson LW, Tranberg M, Christensen PN, Brøndum R, Wentzensen N, Clarke MA, et al. Clinical utility of p16/Ki67 dual-stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: a cross-sectional study. BJOG. 2023;130(2):202-209.
1. Zheng M, Hou L, Ma Y, Zhou L, Wang F, Cheng B, et al. Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors. Mol Cancer. 2019;18(1):76.
1. Dubey H, Ranjan A, Durai J, Khan MA, Lakshmy R, Khurana S, et al. Evaluation of HE4 as a prognostic biomarker in uterine cervical cancer. Cancer Treat Res Commun. 2023;34:100672.
1. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(Suppl 1):S49-S55.